Adverse Events in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): A Literature Review of Recent Clinical Trials

Horst-Dieter Hummel^1,2*, Max S Topp¹, Ellen T Chang^3,4, Victoria M Chia⁵, Michael A Kelsh⁵, Martha L Doemland³, Shilpa Alekar⁶ and Anthony S Stein⁷

¹Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

²Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany

³Health Sciences Practice, Exponent, Inc., Menlo Park, CA, and Washington, DC, USA

⁴Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA

⁵Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA

⁶Global Safety, Amgen Inc, Thousand Oaks, CA, USA

⁷Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA

^*Corresponding Author: Horst-Dieter Hummel, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany, Tel: +49-931/201-40916, Fax: +49-931/201-640017 Email: